Dr Phillip Williams joined Emergex as Chief Scientific Officer in February 2019. He is responsible for leading the Company’s R&D operations at Milton Park near Oxford.

Phil is a nanotechnology expert, with extensive experience in the field of gold nanoparticle development.

Before joining Emergex, Phil was Principle Scientist at Midatech Pharma where he was involved in the production and validation of the world’s first up-scaling methodologies for ultra-small gold nanoparticles.

Prior to his time at Midatech, Phil was Principal Scientist at Rodaris Pharmaceuticals Ltd where he developed a pre-eclampsia diagnostic for commercial use.

Phil also spent several years at the Glycobiology Institute in Oxford University investigating the N-linked oligosaccharides IgG and, especially, the role of agalactosyl IgG in a range of human diseases and pathologies.